| All Releases |
|---|
 |
Alseres Pharmaceuticals Consolidates Its Offices and Moves into New Headquarters
Aug 19, 2008
|
13.0 KB |
|
| |
HOPKINTON, Mass., Aug 19, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) today announced that following the expiration of its current leases it will consolidate its offices to a new headquarters in Hopkinton, Massachusetts.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080813/NEW056LOGO )
...
|
|
Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results
Aug 13, 2008
|
16.6 KB |
|
| |
HOPKINTON, Mass., Aug 13, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) today reports operational and financial results for the quarter ended June 30, 2008 and provides further information for fiscal year 2008.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080813/NEW056LOGO )
"Alseres mad...
|
|
Alseres Pharmaceuticals to Host 2008 Second Quarter Conference Call
Aug 7, 2008
|
12.1 KB |
|
| |
HOPKINTON, Mass., Aug 07, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE), today announced that they will host a conference call on Thursday, August 14th, 2008 at 9:00am EDT to review the second quarter ending June 30, 2008 and discuss other matters related to the Company.
(Logo: http://www.ne...
|
|
Alseres Pharmaceuticals, Inc. Raises $5 Million
Jun 30, 2008
|
12.4 KB |
|
| |
HOPKINTON, Mass., June 30, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- On June 25, 2008, Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE), a biopharmaceuticals company engaged in the development of therapeutic and diagnostic products primarily for disorders in the central nervous system, entered a into Convertible Promissory Note Purchase Ag...
|
|
Alseres Pharmaceuticals, Inc.'s Chairman, Peter Savas, Reviews Company's Progress in its Annual Letter to Stockholders
Jun 12, 2008
|
15.8 KB |
|
| |
HOPKINTON, Mass., June 12, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) released a letter to stockholders from Peter G. Savas, Chairman and Chief Executive Officer, in conjunction with the company's annual stockholders meeting. The letter which follows, summarizes the Company's progress and des...
|
|
Alseres Pharmaceuticals, Inc. Announces 2008 Annual Stockholders Meeting
May 29, 2008
|
9.8 KB |
|
| |
HOPKINTON, Mass., May 29, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) today announced that the Company will hold its Annual Meeting of Stockholders Thursday, June 12, 2008 at 1:00 p.m. EDT at the offices of Wilmer Cutler Pickering Hale & Dorr, 60 State Street, Boston, MA.
(Logo: http://www...
|
|
Alseres Pharmaceuticals, Inc. Reports First Quarter 2008 Operational and Financial Results
May 14, 2008
|
17.9 KB |
|
| |
HOPKINTON, Mass., May 14, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) today reports operational and financial results for the quarter ended March 31, 2008 and provides further information for fiscal year 2008. Recent highlights include:
- Encouraging 12 month interim results from the ...
|
|
Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury
May 12, 2008
|
15.6 KB |
|
| |
HOPKINTON, Mass., May 12, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) today announced 12-month interim data from its Phase I/IIa clinical trial of Cethrin, a proprietary recombinant protein that is being investigated for its potential to restore motor and sensory function after spinal cord inj...
|
|
Alseres Pharmaceuticals to Host 2008 First Quarter Conference Call
May 9, 2008
|
12.1 KB |
|
| |
HOPKINTON, Mass., May 9, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE), today announced that they will host a conference call on Thursday, May 15th, 2008 at 9:00am EDT to review the first quarter ending March 31, 2008 and discuss other matters related to the Company.
(Logo: http://www.newsco...
|
|
Alseres Pharmaceuticals Enters Agreement to Amend Cethrin(R) License to Lower Milestone Payments and Royalty Rates
May 6, 2008
|
13.7 KB |
|
| |
HOPKINTON, Mass., May 6, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE), today announced an agreement with BioAxone Therapeutic, Inc., of Montreal, Canada, whereby, upon payment by Alseres of an option fee of $7 million on or before October 27, 2008, Alseres may exercise an option to amend the Co...
|
|
Alseres Pharmaceuticals, Inc. to Present at The Neurotech Industry Investing & Partnering Conference
May 5, 2008
|
10.2 KB |
|
| |
HOPKINTON, Mass., May 5, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) today announced that the Company will participate in a panel entitled "Traumatic Brain and Spinal Cord Injury" at the Neurotech Industry Investing & Partnering Conference in Boston, MA, Thursday, May 8, 2008. The session will...
|
|
Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
Apr 17, 2008
|
14.5 KB |
|
| |
HOPKINTON, Mass., April 17, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) announced today that seven sites for the first stage of the ALTROPANE(R) Parkinson's or Essential Tremor - 2 (POET-2) Phase III clinical trial program are now open for patient enrollment. ALTROPANE molecular imaging agent ...
|
|
Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at 'Working 2 Walk' in Washington, DC, April 13-15, 2008
Apr 9, 2008
|
13.1 KB |
|
| |
HOPKINTON, Mass., April 9, 2008, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) announced that on April 15, 2008, Dr. Mark Hurtt, Chief Medical Officer, will discuss the CETHRIN development program as a member of an expert panel on Spinal Cord Injury Research during a congressional briefing on Ca...
|
|
Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights
Mar 31, 2008
|
21.9 KB |
|
| |
HOPKINTON, Mass., March 31, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) today reported consolidated financial results for the year ended December 31, 2007 and company highlights.
(Logo: http://www.newscom.com/cgi-bin/prnh/20070608/NEF043LOGO )
"2007 was a year of significant clinical, ...
|
|
Alseres Pharmaceuticals, Inc. Complies With NASDAQ Rule Regarding Recently Filed 10-K
Mar 31, 2008
|
11.3 KB |
|
| |
HOPKINTON, Mass., March 31, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) today announced that the report of the Company's independent registered public accounting firm regarding the Company's 2007 financial statements contained an explanatory paragraph regarding the Company's ability to continu...
|
|
Alseres Pharmaceuticals to Host 2007 Financial Results Conference Call
Mar 25, 2008
|
11.6 KB |
|
| |
HOPKINTON, Mass., March 25, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) today announced that the Company will host a conference call on Tuesday, April 1st, 2008 at 10:00am EDT to review 2007 Financial Results and discuss other matters related to the Company.
To access the conference call, ...
|
|
Alseres Pharmaceuticals, Inc. Raises $5 Million
Mar 20, 2008
|
11.8 KB |
|
| |
HOPKINTON, Mass., March 20, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) today announced that it entered into a Third Amended and Restated Convertible Promissory Note Purchase Agreement dated as of March 18, 2008, among Robert L. Gipson, Thomas Gipson, Arthur Koenig, Ingalls & Snyder Value Part...
|
|
Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
Mar 10, 2008
|
12.7 KB |
|
| |
HOPKINTON, Mass., March 10, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) announced that data from preclinical studies of the Company's nerve repair candidate, Inosine, and DAT Blocker product candidates from its neurodegeneration program were presented at the ASENT conference, March 6-8, 2008 i...
|
|
Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
Jan 7, 2008
|
13.1 KB |
|
| |
HOPKINTON, Mass., Jan 07, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Alseres Pharmaceuticals, Inc., (Nasdaq: ALSE), announced today that it has concluded enrollment in the Phase I/IIa clinical trial of Cethrin in acute spinal cord injury (SCI). A total of 48 subjects have been enrolled at 9 sites in the United States and Canada. We expe...
|
|
Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
Dec 18, 2007
|
13.5 KB |
|
| |
HOPKINTON, Mass., Dec 18, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Alseres Pharmaceuticals, Inc., (Nasdaq: ALSE), announced today that it has enrolled the first subject in the initial stage of the ALTROPANE(R) Parkinson's or Essential Tremor - 2 (POET-2) Phase III clinical trial program. This subject was enrolled at the University of ...
|
|
|
